Product Highlight - Cavsamir

29 Sep 2021
• Cavsamir® is the first generic of sevelamer carbonate 800 mg tablet in Malaysia indicated for the control of hyperphosphataemia in adult patients receiving haemodialysis or peritoneal dialysis, also for adult patients with chronic kidney disease not on dialysis with serum phosphorus ≥1.78 mmol/L.1
• Dr. Reddy’s sevelamer is approved by US FDA and it is bioequivalent and therapeutically equivalent to the reference product.2
• Sevelamer is the only non-calcium phosphate binder that does not accumulate.3
• Sevelamer lower risk of hospitalization and improves survival compared to calcium-based phosphate binder.4

References:
1) Cavsamir® prescribing information
2)
Data on file
3) Drugs. 2013 May;73(7):673-88
4)
Nephro Dial Transplant. 2017;32(1):111-125



For Healthcare Professional Only
DRL/MY/CV-030/Jun2021

Related MIMS Drugs

Editor's Recommendations